Drug Trial Radar · NCT05105841
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Nov 8, 2021
Primary completion
Oct 9, 2025
Study completion Oct 9, 2025
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Nov 3, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries, representing approximately 30% of all adult leukemias. There is a large difference in proportion of malignant lymphoma between the United States (US) and Japan was seen in CLL/small lymphocytic lymphoma (SLL) (Japan, 3.2%; US, 24.1%). The purpose of this study is to assess how well venetoclax works in combination with obinutuzumab (V+G, Cohort 1) or with ibrutinib (V+I, Cohort 2) in Japanese participants with previously untreated CLL/Small Lymphocytic Lymphoma (SLL). Adverse events and change in disease activity will be assessed. Venetoclax is an approved drug for the treatment of CLL and SLL. Study doctors put the participants in 1 of 2 groups, called treatment arms, based on variable alternating assignment. Approximately 20 adult participants with previously untreated CLL/SLL will be enrolled in the study in approximately 20 sites in Japan. Participants in group 1 will receive oral venetoclax + intravenous (IV) obinutuzumab (V+G) in 28-day cycles for a total of 12 cycles, and participants in group 2 will receive oral venetoclax + oral ibrutinib (V+I) in 28-day cycles for a total of 15 cycles. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, and checking for side effects.
Conditions
- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma (SLL)
Interventions
VenetoclaxDrug
Oral Tablet
IbrutinibDrug
Oral Capsule
ObinutuzumabDrug
Intravenous (IV) Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete Remission (CR) and CR With an Incomplete Marrow Recovery (CRi) Rate Per Independent Review Committee (IRC)Time frame: Up to 46 months
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
NHO Nagoya Medical Center /ID# 233523
Nagoya, Aichi-ken, Japan
Aichi Cancer Center Hospital /ID# 238797
Nagoya, Aichi-ken, Japan
Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital /ID# 233524
Nagoya, Aichi-ken, Japan
Chiba Cancer Center /ID# 238839
Chiba, Chiba, Japan
National Hospital Organization Shikoku Cancer Center /ID# 234059
Matsuyama, Ehime, Japan
Kyushu University Hospital /ID# 238437
Fukuoka, Fukuoka, Japan
Hokkaido University Hospital /ID# 238377
Sapporo, Hokkaido, Japan
Hyogo Prefectural Amagasaki General Medical Center /ID# 234082
Amagasaki-shi, Hyōgo, Japan
Tokai University Hospital /ID# 238970
Isehara, Kanagawa, Japan
University Hospital Kyoto Prefectural University of Medicine /ID# 239883
Kyoto, Kyoto, Japan
Tohoku University Hospital /ID# 238433
Sendai, Miyagi, Japan
Niigata University Medical & Dental Hospital /ID# 238324
Niigata, Niigata, Japan
Okayama University Hospital /ID# 238467
Okayama, Okayama-ken, Japan
Kindai University Hospital /ID# 234001
Sakai-shi, Osaka, Japan
Osaka University Hospital /ID# 234037
Suita-shi, Osaka, Japan
Shimane University Hospital /ID# 234076
Izumo-shi, Shimane, Japan
Jichi Medical University Hospital /ID# 238434
Shimotsuke-shi, Tochigi, Japan
National Cancer Center Hospital /ID# 232449
Chuo-ku, Tokyo, Japan
The Cancer Institute Hospital Of JFCR /ID# 232450
Koto-ku, Tokyo, Japan
Yamagata University Hospital /ID# 234032
Yamagata, Yamagata, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.